HIV 1002

Human papillomavirus infection and disease in
men: Impact of HIV

S
Delany-Moretlwe,1 MB BCh, PhD,
DTM&H; A Chikandiwa,1 MB BCh, MPH; J Gibbs,1,2 MB ChB, MRCP, MSc

1
Wits Reproductive Health and HIV Institute,
University of the Witwatersrand, Johannesburg, South Africa

2
London School of Hygiene and Tropical
Medicine, London, United Kingdom

Corresponding

author:
S Delany-Moretlwe
(sdelany@wrhi.ac.za)

There is growing evidence of a significant
burden of human papillomavirus (HPV) infection and associated
disease in men. High rates of HPV infection have been observed
in men from sub-Saharan Africa where HIV prevalence is high. HIV
infection increases HPV prevalence, incidence and persistence
and is strongly associated with the development of anogenital
warts and anal, penile and head and neck cancers in men. Despite
increasing access to antiretroviral therapy, there appears to be
little benefit in preventing the development of these cancers in
HIV-positive men, making prevention of infection a priority. New
prevention options that are being introduced in many African
countries include male circumcision and HPV vaccination.
However, more data are needed on the burden of HPV disease in
men before boys are included in HPV vaccination programmes.

S Afr J HIV Med 2013;14(4):183-188. DOI:10.7196/SAJHIVMED.1002

Human papillomavirus (HPV) is

a common sexually transmitted infection (STI) affecting both
men and women.1 HPV infections can be
classified as either low- (LR) or high-risk (HR).
2
HR-HPV infections have been associated with cancer of the
anogenital and oropharyngeal tissues. While the
majority of HPV infections are transient and clear
spontaneously, persistent infection with HR-HPV is associated
with the development of pre-neoplastic and neoplastic lesions
in these areas (Fig. 1). While much is known about the natural
history of HPV infection in cervical cancer in women, less is
known about the development of HPV-associated disease in men.
Emerging evidence points to a significant role for HIV
infection in promoting HPV prevalence, incidence and
persistence. This review provides an update on
current evidence regarding the epidemiology of HPV infection
and disease in men, the effects of HIV on HPV infection and
disease in men in sub-Saharan Africa (SSA), and the prospects
for prevention in this setting.

Fig. 1. Natural course of genital HR-HPV infection (source:
Stanley
82
).

Global burden of HPV

HPV infection is ubiquitous in men. A
systematic review of 62 studies using reliable methods of HPV
DNA detection and conducted prior to 2009, representing 14 800
men in 23 countries, showed that anogenital HPV DNA prevalence
is generally high in sexually active men. The review
highlighted considerable variation in estimates
by region, from 1% to 84% in LR men, to 2% to 93% in HR men.3
Compared with studies in women, peak prevalence spanned a wide
range of ages, suggesting that men have the potential for
longer-term persistence of infection or higher rates of
re-infection.3 Type-specific HPV
seroprevalence studies are better indicators of lifetime
exposure to HPV infection, although they may underestimate
cumulative HPV exposure, given that not all
infections lead to seroconversion.4
Recent population-based studies have estimated the prevalence
of antibodies to vaccine-preventable HPV types 6, 11, 16 and
18. Among men aged 14 - 59 years in the USA, 12.2% of men were
seropositive for any vaccine type, with a peak prevalence of
18% among men aged 50 - 59 years.5 In
a similar population-based study in Australia, peak prevalence
of any vaccine type was 31.5% among men aged 40 - 49 years;6 and
a study from the Netherlands estimated that the seroprevalence
of any HR-HPV in men aged ≥14 years
was 20%.7
There is some evidence that seroprevalence appears to be
rising as a result of changes in sexual behaviour and earlier
age of sexual debut. In a related study from the Netherlands
comparing serosurveillance rates of HR-HPV in the periods 1995
- 1996 and 2006 - 2007, overall HR-HPV
seroprevalence rates were significantly higher in the later
survey, compared with the earlier survey across all age
groups.8

Burden of infection in SSA

A recent global review of 117 studies
worldwide suggests that the seroprevalence of HPV is even higher
in SSA, although data on men in SSA are sparse.4 In a
small study of Tanzanian genital ulcer disease (GUD) patients,
pregnant women and male blood donors, the prevalence of
antibodies to HR-HPV ranged from 77% in male GUD patients to 15%
in male blood donors. In this study, the prevalence of
antibodies to HPV types 16, 18, 51 and 52 was considerably
higher in HIV-positive patients with GUD.9

Although data on anogenital HPV DNA prevalence in men in
SSA are also limited,3 overall reported
prevalences in men are high, ranging from 19% to 78%.10-15
In most, but not all studies, the most prevalent type was
HPV-16.15
The observed heterogeneity in estimates can be attributed to
differences in age distribution, sexual behaviour and HIV
prevalence within the different populations. Emerging data
suggest that the incidence of HR anogenital HPV infection in
men is also high, ranging from 35.7/100 person years in South
African men to 40/100 person-years in East African men
participating in male circumcision (MC) trials.16-18
In both settings, the risk of HPV acquisition was doubled in
HIV-positive men. These incidence rates are much higher than
those previously observed elsewhere.19
,
20

Factors associated with HPV infection

HPV seroprevalence rates are consistently
lower in men than in women,[6,21
,22] with men also producing
lower antibody titres than women. 23 There
are several plausible biological explanations for differences
in antibody responses between men and women. Men may experience
a higher frequency of transient infections, a lower viral load,
or produce less robust immunological responses than women.
24
It has been argued that the site of infection and/or type of
epithelium influence antibody responses, with men experiencing a
higher proportion of infections in more keratinised tissues
(e.g. penile shaft) than women (e.g. anal canal or cervix).
Thicker, more keratinised epithelium may present a barrier to
infection, and if infected, may be less likely than mucosal
surfaces to induce an immune response, given the relative
distance from draining lymphatics and lymph nodes. 23
,
25
Recent data from a study comparing type-specific HPV antibody
prevalence with the corresponding prevalence of HPV DNA
detected in the external genitalia and anal canal in
heterosexual men and men who have sex with men (MSM) support
this notion. Higher HPV-6 and -16 seroprevalence rates were
observed in men that had a same HPV-type infection in the anal
canal, than in those with the same HPV-type infection in the
external genitalia only. Higher seroprevalence rates were also
observed in MSM compared with heterosexual men.26

The association between HPV infection and age is somewhat
inconsistent, with fairly flat prevalence curves reported in
populations where HIV prevalence is relatively low. 3
,
27 Data
emerging from Africa, present a similarly mixed picture. A
study among Kenyan fishermen showed a lower risk for HPV
infection in older age groups,10 while data from Kenyan men
participating in an MC trial showed little variation in
prevalence with age.28 A more recent study in men
from Tanzania demonstrated an association between increasing age
and HPV prevalence, but that this association was driven by
HIV-positive men.15
Two recent incidence studies confirmed that increasing age is
associated with a lower risk for HPV infection.16
,
17
Combined, these data tend to suggest that the association
between HPV infection and age in men in SSA is related to
patterns of sexual activity, but confounded by HIV status, which
may promote the persistence of HPV infection.

Sexual behaviour is an important risk factor for
anogenital HPV infection. More recent
publications have highlighted the importance of age of sexual
debut,8
marital status,29 high number of
lifetime sexual partners,5
,
30
,
31 number of recent
sexual partners,30 longer history of
sexual activity,30 route of exposure,26
,
30
,
32
and having sex with men32-34 as risk factors
for anogenital HPV infection. Similar
observations about sexual risk behaviour and an association
with HPV have been made in studies of men in SSA.10
,
17
,
28
While the data on the protective effects of condoms are
somewhat mixed,35 evidence

from African studies in men show a reduced risk of genital HPV
infection associated with condom use.10
,
28
,
36
,
37
Evidence from randomised controlled trials (RCTs) of MC has
conclusively demonstrated the protective benefits of MC in
reducing the risk of HPV prevalence and incidence.[17,36,
38,39]
Related findings from the trial in Kenya have highlighted less
frequent bathing as a risk factor for HPV infection, which may
be associated with poor genital hygiene in uncircumcised men.18
,
28

STIs are independently associated with the risk of HPV
infection, particularly chlamydia,19
,
30 herpes simplex virus
(HSV)-2,34
and hepatitis B.40
While they may share a common mode of transmission, STIs are
thought to increase the risk of HPV infection by facilitating
access to the basal epithelium through micro-abrasions in the
skin.35
Recent reports on male populations in Africa point to a higher
risk of penile HPV in men co-infected with laboratory-diagnosed
Chlamydia trachomatis or Neisseria
gonorrhoeae, and those who are
HSV-2-seropositive.28
Interestingly, HR-HPV clearance was recently shown to shown to
be higher in HIV-negative men co-infected with syphilis or
HSV-2, suggesting that other genital tract infections may also
create an inflammatory cytokine milieu that may facilitate the
clearance of HPV.17

HIV is a strong risk factor for HPV infection in men. While
studies of anal HPV infection in MSM from Europe and the
Americas first identified an increased risk for infection in
HIV-positive men,24
there is now a growing body of evidence from studies of men in
SSA that shows that prevalent and incident anogenital HPV
infection is more common in HIV-positive men.[15,16,
37] Multiple
infections, particularly with HR-HPV, are more common in
HIV-positive men.13
,
41
Prevalence of infection increases with declining CD4+ count.42 Partner
HIV status has also been shown to increase the risk of HPV
detection in men.14
,
43

Anogenital warts

Anogenital warts (AGWs) are the most
common clinical manifestation of HPV infection.44
Caused mainly by infection with HPV-6 and -11,45
they are highly infectious. An estimated 65% of
people whose sexual partner has genital warts will develop
warts themselves. 46
The estimated incubation period from HPV infection to genital
wart development is 2 weeks - 8 months.47
While approximately 20 - 30% of genital warts will
spontaneously regress,48 recurrence is

common, resulting in significant psychological morbidity and
high medical costs for repeated treatment. These costs are not
insignificant when compared with costs for treatment of
cervical cancer in women.49 Two recent reviews
estimated the prevalence and incidence of AGWs in the general
adult population worldwide45 and in SSA,50
respectively.. Worldwide, the overall
prevalence of AGWs, based on genital examinations, ranged from
0.2% to 5.1%, with higher prevalence rates observed in males.
Data suggest that prevalence has increased in recent decades,
possibly as a result of changes in sexual behaviour.

Studies in male populations in SSA suggest much higher
prevalence rates than in high-income countries, possibly as a
result of higher HIV prevalence rates. Highest rates of 4.8 -
12.2% have been observed in HR men from Central and South
Africa, a region of high HIV prevalence. Lack of circumcision
and HIV infection have been identified as risk factors for
AGWs in men.12 Importantly, HIV-positive

men with AGWs may also be at risk for infection with HR-HPV.
In a small study in Johannesburg among HIV-positive men with
penile warts, 85% were found to have HR-HPV as well. HPV-16
and -18 were most frequently detected.41
These high rates of HR-HPV detection in men with HIV suggest
that they are at significant risk for the future
development of pre-neoplastic and neoplastic lesions,
emphasising the importance of targeting screening programmes
for HIV-positive men with AGWs.

Anal cancer

While relatively uncommon, the incidence
of anal cancer in men appears to be rising.51 A
systematic review examined these trends, and found that
age-adjusted incidence rates for anal cancer have increased in
several high-income countries, with HPV infection identified
as the most important associated aetiological factor.52
Besides increasing age, smoking, receptive anal intercourse
and HIV infection were the most important risk factors for
anal cancer, with the highest incidence rates observed in
HIV-positive MSM. While anal cancer incidence is highest in
HIV-positive MSM, it should be noted that receptive anal
intercourse is not a prerequisite for anal HPV infection,
pre-cancer lesions or anal cancer. Piketty et al.53
demonstrated high rates of anal infection and squamous
intraepithelial lesions in HIV-positive men with no previous
history of anal intercourse – an observation made subsequently
in other studies.54 In such instances,
anal HPV infection is thought be transferred to the anal canal
through transiently infected fingers or toys, as well as by
shedding from other infected genital sites.

Anal cancer is considered to be biologically similar to
cervical cancer. Like cervical cancer, it is thought to be
preceded by a spectrum of intraepithelial changes and anal
intraepithelial neoplasia (AIN), which can be graded similarly
to cervical cancer. While there is strong supportive evidence
that high-grade AIN is a precursor to invasive cancer, there
is no consensus regarding the prevalence or significance of
AIN, nor on the rate of AIN progression to cancer. Almost all
of the natural history data come from studies in MSM, with few
data on heterosexual, HIV-negative or African populations. A
recent meta-analysis of anal HPV and associated lesions in MSM
found that HIV-positive men were consistently more likely to
be infected with HPV, to have associated lesions, and to have
higher rates of anal cancer, although the excess in
HIV-positive men was smallest for high-grade AIN, and was not
statistically significant for that category. While there were
no data on progression rates of AIN to cancer, estimates from
this analysis suggest that rates of progression are
significantly lower than those observed in cervical cancer.55
Despite significant heterogeneity in the data, and a lack of
prospective data, it remains plausible that high-grade

AIN lesions regress more frequently than high-grade cervical
lesions. 56 While the prevention
of anal cancers in high-risk HIV-positive men is a priority,
these findings raise doubts about the utility of anal cancer
screening programmes at present. Until further evidence of
benefit for screening in terms of reductions in anal cancer
incidence and mortality become available, anal cancer
screening programmes for men are likely to be controversial.

Despite immune reconstitution associated with highly
active antiretroviral therapy (HAART), there appears to be
little evidence that this therapy has a preventive effect on
the development of anal cancer. The recent meta-analysis and

other analyses of temporal trends in anal cancer incidence
have highlighted the continuing high incidence of anal cancer,
despite the widespread introduction of HAART. 55
,
57
,
58
These data suggest that prolonged survival afforded by HAART
initiation may allow more time for AIN to progress to cancer,
thus leading to higher anal cancer rates.

Penile cancer

Penile cancers are relatively rare. In
2008, of the estimated 22 000 new penile cancer
cases, half were attributable to HPV, with much higher rates
observed in regions with a low human development index.59
Data from Zimbabwe suggest that southern Africa has higher
incidence rates,60 and a
recently published report of HPV detection in cancerous and
pre-cancerous penile lesions from men in South Africa
demonstrated multiple HPV infections, with high rates of
HPV-16.61
Risk factors for penile cancer include: a lack of MC; phimosis
and/or poor genital hygiene; AGWs; and HIV infection.
HIV-positive men have an eight-fold increased risk of penile
cancer, which may be associated with higher HPV infection
rates.62
Other risk factors for penile cancer that have been reported
include current smoking, early age of first sexual
intercourse, high lifetime number of female sexual partners,
lack of condom use, chronic inflammatory conditions including
balanitis and lichen sclerosus, and treatment with ultraviolet
photochemotherapy for psoriasis.63

Head and neck
squamous cell carcinomas

Head and neck cancer commonly refers to
squamous cell carcinomas (SCCs) arising in the upper
aerodigestive tract (oral cavity, nasopharynx, hypopharynx and
larynx). Traditionally, most head and neck cancers were
associated with tobacco and alcohol exposures and presented
after the age of 60 years. More recently, a shift in the
epidemiology of oropharyngeal SCC has been observed, with a
rising incidence, particularly in the palatine tonsils and base
of the tongue, occurring in younger age groups and in people who
have never smoked. 64 Like the cervix and anus,
there is an epithelial transition zone within the oropharynx
which is prone to HPV infection, dysplasia and the development
of SCCs. In a systematic review of studies involving
histological specimens of head and neck SCCs, in 36% HPV DNA was
detected, and HPV-16 was the most common HPV type associated
with head and neck SCC.65 HIV-infected individuals
have a 1.5 - four-fold higher risk of oropharyngeal or tonsillar
cancer than the general population. Although the proportion of
oropharyngeal cancers is unknown, HIV-positive individuals
appear to be at moderately increased risk of HPV-associated head
and neck SCC compared with the general population.66 D’Souza
et al.67 showed convincing evidence
that oral cavity HPV DNA infection was related to sexual
behaviour, including oral sex. There is evidence that
HIV-positive individuals have a higher prevalence of oral
HR-HPV, even after controlling for sexual behaviour,68 and that
the risk for infection appears to be higher among those with a
declining CD4+
count.69
While there are limited data on the natural history of oral HPV
infection, the majority of infections clear within two years,70 although
persistence appears to be associated with a CD4+ count
<500 cells/μl.71
There do not appear to be benefits for HAART on either the
persistence of HPV infection or the clearance of oral lesions,
but more evidence is needed in this regard.66 Data on
oral HPV and HPV-associated head and neck SCC in African
populations is currently scarce, although one study from
Senegal,72
which included 117 invasive head and neck cancer histology
specimens, mainly from men with a mean age of 52 years, found
only four cases to be positive for HPV DNA. The authors remarked
that larger studies are needed to confirm these findings and
explore other potential risk factors specific to the region.72

Prevention of HPV-associated infection and
disease in men

Evidence for the benefit of several strategies
to prevent HPV infection and subsequent disease in men has
emerged in recent years. Studies have shown a greater protective
effect of condoms in the prevention of HPV acquisition in men.
Analysis of data from a multi-national cohort study in men
showed a two-fold lower risk of HPV acquisition in men with no
steady partner and who always used condoms. In addition, the
probability of clearing an oncogenic infection was 30% higher in
men who consistently used condoms with non-steady partners.73
Consistent condom use has also been associated with the
regression of penile lesions in men.74 Recent RCTs in Africa
provide strong evidence that MC is protective against HPV
infection. In these trials, MC has been associated with
reductions in the incidence, prevalence and persistence of HPV
infection in men. In HIV-negative men, MC has also been shown to
reduce HR-HPV transmission to female partners.75 Recent
data suggests that decreased penile shedding of HR-HPV observed
in HPV-infected circumcised men may help to explain the
protective effects observed for female partners.38 MC has
also been associated with a lower prevalence of flat penile
lesions in men.39

Vaccines are the ideal form of primary prevention for
infectious diseases, and have been successful in the control
of many other infectious diseases. Having been shown to be
efficacious in women, HPV vaccine studies have
now demonstrated evidence of benefit in men. An RCT involving
4 065 men from 18 countries aged 16 - 26 years showed that the
quadrivalent vaccine was 90% effective in preventing infection
with vaccine-specific types in the per protocol analysis, and
89% effective in preventing AGWs in the same population.76 In
602 MSM aged 16 - 26 years, the quadrivalent
vaccine was 77.5% effective in preventing HPV-6-, -11-, -16-
and -18-associated AIN.77 The bivalent vaccine
is not currently registered for use in men. HPV vaccination
has been shown to be safe and highly immunogenic in HIV-1
infected men.78 Modelling studies
predict benefits of vaccination for boys, when high levels of
vaccine coverage are achieved in girls,79
and data emerging from countries where national vaccination
programmes have been introduced confirm this. Even though
vaccination was restricted to girls, in Australia, there has
been an 82% decline in AGWs in men aged <21 years since the
introduction of the vaccine.80 In Denmark, a 50%
decline in AGWs in young men aged <19 years was observed
only three years post vaccine introduction.

81 However,

these benefits may not translate to all men, particularly MSM
who may not benefit from herd immunity. Australia is the first
country to extend vaccination to men. While several countries
in Africa have recently introduced HPV vaccination programmes,
these school-based programmes do not include boys. Further
evidence is needed of the HPV-associated burden of disease in
men, and the potential effects of HIV on HPV-associated
disease in men before the vaccination of boys can be
considered in lower-resource settings.

Conclusion

HPV infection and associated disease are
common in men in SSA. While data on the burden of disease are
limited, studies suggest that infection with HPV is common,
particularly in the context of HIV. There is also growing
evidence to suggest that HIV infection enhances HPV persistence
– a precursor for the development of cancer. Given expanding
access to HAART in Africa, there is now potential for
significant morbidity and mortality from HPV-related cancers in
men in the future. While MC and HPV vaccination programmes are
being rolled out in many African countries where the burden of
HIV is high, more data are needed on the natural history and
burden of HPV-associated disease in men in Africa to inform the
development of prevention programmes.

References

1. International

Agency for Research on Cancer. Monographs on the Evaluation
of Carcinogenic Risks to Humans 2007;90.

1. International

Agency for Research on Cancer. Monographs on the Evaluation
of Carcinogenic Risks to Humans 2007;90.

2. de
Villiers EM, Fauquet C, Broker TR, et al. Classification of
papillomaviruses. Virology 2004;324:17-27.

3. Smith JS,
Gilbert PA, Melendy A, et al. Age-specific prevalence of
human papillomavirus infection in males: A global review. J
Adolesc Health 2011;48(6):540-552.
[http://dx.doi.org/10.1016/j.jadohealth.2011.03.010]

4. Tiggelaar
SM, Lin MJ, Viscidi RP, et al. Age-specific human
papillomavirus antibody and deoxyribonucleic acid
prevalence: A global review. J Adolesc Health
2012;50(2):110-131.
[http://dx.doi.org/10.1016/j.jadohealth.2011.10.010]

5. Markowitz
LE, Sternberg M, Dunne EF, et al. Seroprevalence of human
papillomavirus types 6, 11, 16, and 18 in the United States:
National Health and Nutrition Examination Survey 2003-2004.
J Infect Dis 2009;200(7):1059-1067.
[http://dx.doi.org/10.1086/604729]

6. Newall
AT, Brotherton JM, Quinn HE, et al. Population
seroprevalence of human papillomavirus types 6, 11, 16, and
18 in men, women, and children in Australia. Clin Infect Dis
2008;46:1647-1655. [http://dx.doi.org/10.1086/587895]

7. Scherpenisse

M, Mollers M, Schepp RM, et al. Seroprevalence of seven
high-risk HPV types in The Netherlands. Vaccine
2012;30(47):6686-6693.
[http://dx.doi.org/10.1016/j.vaccine.2012.08.068]

7. Scherpenisse

M, Mollers M, Schepp RM, et al. Seroprevalence of seven
high-risk HPV types in The Netherlands. Vaccine
2012;30(47):6686-6693.
[http://dx.doi.org/10.1016/j.vaccine.2012.08.068]

8. Scherpenisse

M, Mollers M, Schepp RM, et al. Changes in antibody
seroprevalence of seven high-risk HPV types between
nationwide surveillance studies from 1995-96 and 2006-07 in
The Netherlands. PLoS One, 2012;7(11):e48807.
[http://dx.doi.org/10.1371journal.pone.0048807]

8. Scherpenisse

9. Mbwana J,
Viscidi R, Lyamuya E, et al. Prevalence of serum antibodies
to human papilloma virus in patients with genital ulcer
disease in an urban population of Tanzania. Sex Transm
Infect 2007;83(1):64-65.

10. Ng'ayo
MO, Bukusi E, Rowhani-Rahbar A, et al. Epidemiology of human
papillomavirus infection among fishermen along Lake Victoria
Shore in the Kisumu District, Kenya. Sex Transm Infect
2008;84(1):62-66.

11. Auvert
B, Sobngwi-Tambekou J, Cutler E, et al. Effect of male
circumcision on the prevalence of high-risk human
papillomavirus in young men: Results of a randomized
controlled trial conducted in Orange Farm, South Africa. J
Infect Dis 2009;199(1):14-19.

12. Smith
JS, Moses S, Hudgens MG, et al. Increased risk of HIV
acquisition among Kenyan men with human papillomavirus
infection. J Infect Dis 2010;201:1677-1685.
[http://dx.doi.org/10.1086/652408]

13. Müller
EE, Chirwa TF, Lewis DA. Human
papillomavirus (HPV) infection in heterosexual South African
men attending sexual health services: Associations between
HPV and HIV serostatus. Sex Transm Infect 2010;86:175-180.

14. Veldhuijzen

NJ, Dhont N, Vyankandondera J, et al. Prevalence and
concordance of HPV, HIV, and HSV-2 in heterosexual couples
in Kigali, Rwanda. Sex Transm Dis 2012;39(2):128-135.
[http://dx.doi.org/10.1097/OLQ.0b013e3182367c4c]

14. Veldhuijzen

15. Olesen
TB, Iftner T, Mwaiselage J, et al. Prevalence and type
distribution of human papillomavirus among 1813 men in
Tanzania and the relationship to HIV status. Sex Transm Dis
2013;40(7):592-598.
[http://dx.doi.org/10.1097/OLQ.0b013e31828fcf57]

16. Mbulawa
ZZ, Marais DJ, Johnson LF, et al. Impact of human
immunodeficiency virus on the natural history of human
papillomavirus genital infection in South African men and
women. J Infect Dis 2012;206:15-27.
[http://dx.doi.org/10.1093/infdis/jis299]

17. Tobian
AA, Kigozi G, Gravitt PE, et al. Human papillomavirus
incidence and clearance among HIV-positive and HIV-negative
men in sub-Saharan Africa. AIDS 2012;26(12):1555-1565.
[http://dx.doi.org/10.1097/QAD.0b013e328353b83c]

18. Backes
DM, Snijders PJ, Hudgens MG, et al. Sexual behaviour and
less frequent bathing are associated with higher human
papillomavirus incidence in a cohort study of uncircumcised
Kenyan men. Sex Transm Infect 2013;89(2):148-155.
[http://dx.doi.org/10.1136/sextrans-2012-050532]

19. Kjaer
SK, Munk C, Winther JF, et al. Acquisition and persistence
of human papillomavirus infection in younger men: A
prospective follow-up study among Danish soldiers. Cancer
Epidemiol Biomarkers Prev 2005;14:1528-1533.

20. Giuliano
AR, Lee JH, Fulp W, et al. Incidence and clearance of
genital human papillomavirus infection in men (HIM): A
cohort study. Lancet 2011;377(9769):932-940.
[http://dx.doi.org/10.1016/S0140-6736(10)62342-2]

21. Stone
KM, Karem KL, Sternberg MR, et al. Seroprevalence of human
papillomavirus type 16 infection in the United States. J
Infect Dis 2002;186:1396-1402.

22. Thompson
DL, Douglas JM Jr, Foster M, et al. Seroepidemiology of
infection with human papillomavirus 16, in men and women
attending sexually transmitted disease clinics in the United
States. J Infect Dis 2004:190:1563-1574.

23. Slavinsky

J, Kissinger P, Burger L, et al. Seroepidemiology of low and
high oncogenic risk types of human papillomavirus in a
predominantly male cohort of STD clinic patients. Int J STD

AIDS 2001;12:516-523.

23. Slavinsky

J, Kissinger P, Burger L, et al. Seroepidemiology of low and
high oncogenic risk types of human papillomavirus in a
predominantly male cohort of STD clinic patients. Int J STD

AIDS 2001;12:516-523.

24. Partridge

JM, Koutsky LA. Genital human
papillomavirus infection in men. Lancet Infect Dis
2006;6(1):21-31.

24. Partridge

JM, Koutsky LA. Genital human
papillomavirus infection in men. Lancet Infect Dis
2006;6(1):21-31.

25. Edelstein

ZR, Carter JJ, Garg R, et al. Serum antibody response
following genital α9 human
papillomavirus infection in young men. J Infect Dis
2011;204:209-216. [http://dx.doi.org/10.1093/infdis/jir242]

25. Edelstein

ZR, Carter JJ, Garg R, et al. Serum antibody response
following genital α9 human
papillomavirus infection in young men. J Infect Dis
2011;204:209-216. [http://dx.doi.org/10.1093/infdis/jir242]

26. Lu B,
Viscidi RP, Wu Y, et al. Seroprevalence of human
papillomavirus (HPV) type 6 and 16 vary by anatomic site of
HPV infection in men. Cancer Epidemiol Biomarkers Prev
2012;21(9):1542-1546.
[http://dx.doi.org/10.1158/1055-9965.EPI-12-0483]

27. Giuliano
AR, Lazcano-Ponce E, Villa LL, et al. The human
papillomavirus infection in men study: Human papillomavirus
prevalence and type distribution among men residing in
Brazil, Mexico, and the United States. Cancer Epidemiol
Biomarkers Prev 2008;17:2036-2043.
[http://dx.doi.org/10.1158/1055-9965.EPI-08-0151]

28. Smith
JS, Backes DM, Hudgens MG, et al. Prevalence and risk
factors of human papillomavirus infection by penile site in
uncircumcised Kenyan men. Int J Cancer 2010;126(2):572-577.
[http://dx.doi.org/10.1002/ijc.24770]

29. Lu B,
Hagensee ME, Lee JH, et al. Epidemiologic factors associated
with seropositivity to human papillomavirus type 16 and 18
virus-like particles and risk of subsequent infection in
men. Cancer Epidemiol Biomarkers Prev 2010;19(2):511-516.
[http://dx.doi.org/10.1158/1055-9965.EPI-09-0790]

30. Poynten
IM, Waterboer T, Jin F, et al. Human papillomavirus types 6
and 11 seropositivity: Risk factors and association with
ano-genital warts among homosexual men. J Infect
2013;66(6):503-511.
[http://dx.doi.org/10.1016/j.jinf.2013.03.005]

31. Mooij
SH, van der Klis FR, van der Sande MA, et al.
Seroepidemiology of high-risk HPV in HIV-negative and
HIV-infected MSM: The H2M study. Cancer Epidemiol Biomarkers
Prev 2013;22(10):1698-1708.
[http://dx.doi.org/10.1158/1055-9965.EPI-13-0460]

32. Heiligenberg

M, Alberts CJ, Waterboer T, et al. Route of sexual exposure
is independently associated with seropositivity to HPV-16
and HPV-18 among clients of an STI clinic in the
Netherlands. J Infect Dis 2013;208(7):1081-1085.

32. Heiligenberg

33. Lu B,
Viscidi RP, Lee JH, et al. Human papillomavirus (HPV) 6, 11,
16, and 18 seroprevalence is associated with sexual practice
and age: Results from the multinational HPV Infection in Men
Study (HIM Study). Cancer Epidemiol Biomarkers Prev
2011;20(5):990-1002.
[http://dx.doi.org/10.1158/1055-9965.EPI-10-1160]

34. Heiligenberg

M, Michael KM, Kramer MA, et al. Seroprevalence and
determinants of eight high-risk human papillomavirus types
in homosexual men, heterosexual men, and women: A
population-based study in Amsterdam. Sex Transm Dis
2010;37(11):672-680.
[http://dx.doi.org/10.1097/OLQ.0b013e3181e71069]

34. Heiligenberg

35. Veldhuijzen

NJ, Snijders PJ, Reiss P, et al. Factors affecting
transmission of mucosal human papillomavirus. Lancet Infect
Dis 2010;10:862-874.
[http://dx.doi.org/10.1016/S1473-3099(10)70190-0]

35. Veldhuijzen

NJ, Snijders PJ, Reiss P, et al. Factors affecting
transmission of mucosal human papillomavirus. Lancet Infect
Dis 2010;10:862-874.
[http://dx.doi.org/10.1016/S1473-3099(10)70190-0]

36. Tarnaud
C, Lissouba P, Cutler E, et al. Association of low-risk
human papillomavirus infection with male circumcision in
young men: Results from a longitudinal study conducted in
Orange Farm (South Africa). Infect Dis Obstet Gynecol
2011;2011:567408. [http://dx.doi.org/10.1155/2011/567408]

37. Tobian
AA, Grabowski MK, Kigozi G, et al. High-risk human
papillomavirus prevalence is associated with HIV infection
among heterosexual men in Rakai, Uganda. Sex Transm Infect
2013;89(2):122-127.
[http://dx.doi.org/10.1136/sextrans-2012-050524]

38. Wilson
LE, Gravitt P, Tobian AA, et al. Male circumcision reduces
penile high-risk human papillomavirus viral load in a
randomised clinical trial in Rakai, Uganda. Sex Transm
Infect 2013;89(3):262-266.
[http://dx.doi.org/10.1136/sextrans-2012-050633]

39. Backes
DM, Bleeker MC, Meijer CJ, et al. Male circumcision is
associated with a lower prevalence of human
papillomavirus-associated penile lesions among Kenyan men.
Int J Cancer 2012;130(8):1888-1897.
[http://dx.doi.org/10.1002/ijc.26196]

40. Nyitray
A, Nielson CM, Harris RB, et al. Prevalence of and risk
factors for anal human papillomavirus infection in
heterosexual men. J Infect Dis 2008;197:1676-1684.
[http://dx.doi.org/10.1086/588145]

41. Firnhaber

C, Sello M, Maskew M, et al. Human papillomavirus types in
HIV seropositive men with penile warts in Johannesburg,
South Africa. Int J STD AIDS 2011;22(2):107-109.
[http://dx.doi.org/10.1258/ijsa.2010.010306]

41. Firnhaber

42. Mbulawa
ZZ, Marais DJ, Johnson LF, et al. Influence of human
immunodeficiency virus and CD4 count on the prevalence of
human papillomavirus in heterosexual couples. J Gen Virol
2010;91:3023-3031.
[http://dx.doi.org/10.1099/vir.0.020669-0]

43. Mbulawa ZZ,
Marais DJ, Johnson LF, et al. Influence of human
immunodeficiency virus and CD4 count on the prevalence of
human papillomavirus in heterosexual couples. J Gen Virol 2010
91(Suppl 12):3023-3031.

44. Scheurer ME,
Tortolero-Luna G, Adler-Storthz K. Human papillomavirus
infection: Biology, epidemiology, and prevention. Int J
Gynecol Cancer 2005:15:727-774.

45. Patel H,
Wagner M, Singhal P, Kothari S. Systematic review of the
incidence and prevalence of genital warts. BMC Infect Dis
2013;13:39. [http://dx.doi.org/10.1186/1471-2334-13-39]

46. Lacey CJ.
Therapy for genital human papillomavirus-related disease. J
Clin Virol 2005;32:S82-S90.

47. Oriel JD.
Natural history of genital warts. Br J Vener Dis 1971;47:1-13.

48. Wiley DJ,
Douglas J, Beutner K, et al. External genital warts:
Diagnosis, treatment, and prevention. Clin Infect Dis

2002;35:S210-S224.

48. Wiley DJ,
Douglas J, Beutner K, et al. External genital warts:
Diagnosis, treatment, and prevention. Clin Infect Dis

2002;35:S210-S224.

49. Raymakers AJ,
Sadatsafavi M, Marra F, et al. Economic and humanistic burden
of external genital warts. Pharmacoeconomics 2012;30(1):1-16.
[http://dx.doi.org/10.2165/11591170-000000000-00000]

50. Banura C,
Mirembe FM, Orem J, et al. Prevalence, incidence and risk
factors for anogenital warts in Sub Saharan Africa: A
systematic review and meta analysis. Infect Agent Cancer
2013;8(1):27. [http://dx.doi.org/10.1186/1750-9378-8-27]

51. Kurdgelashvili
G, Dores GM, Srour SA, et al. Incidence of potentially human
papillomavirus-related neoplasms in the United States, 1978 to
2007. Cancer 2013;119(12):2291-2299.
[http://dx.doi.org/10.1002/cncr.27989]

52. van der
Zee RP, Richel O, de Vries HJ, Prins JM. The increasing
incidence of anal cancer: Can it be explained by trends in
risk groups? Neth J Med 2013;71(8):401-411.

53. Piketty C,
Darragh TM, Da Costa M, et al. High prevalence of anal human
papillomavirus infection and anal cancer precursors among
HIV-infected persons in the absence of anal intercourse. Ann
Intern Med 2003;183:453-459.

54. Abramowitz L,
Benabderrahmane D, Ravaud P, et al. Anal squamous
intraepithelial lesions and condyloma in HIV-infected
heterosexual men, homosexual men and women: Prevalence and
associated factors. AIDS 2007;21:1457-1465.

55. Machalek DA,
Poynten M, Jin F, et al. Anal human papillomavirus infection
and associated neoplastic lesions in men who have sex with
men: A systematic review and meta-analysis. Lancet Oncol
2012;13(5):487-500.

56. Stanley MA,
Winder DM, Sterling JC, Goon PK. HPV infection, anal
intra-epithelial neoplasia (AIN) and anal cancer: Current
issues. BMC Cancer 2012;12:398.
[http://dx.doi.org/10.1186/1471-2407-12-398]

57. Chiao EY,
Hartman CM, El-Serag HB, Giordano TP. The impact of HIV viral
control on the incidence of HIV-associated anal cancer. J
Acquir Immune Defic Syndr 2013;63:631-663.
[http://dx.doi.org/10.1097/QAI.0b013e3182968fa7]

58. Piketty C,
Selinger-Leneman H, Bouvier AM, et al. Incidence of
HIV-related anal cancer remains increased despite long-term
combined antiretroviral treatment: Results from the french
hospital database on HIV. J Clin Oncol 2012;30(35):4360-4366.
[http://dx.doi.org/10.1200/JCO.2012.44.5486]

59. Forman D, de
Martel C, Lacey CJ, et al. Global burden of human
papillomavirus and related diseases. Vaccine 2012;30(Suppl
5):F12-F23. [http://dx.doi.org/10.1016/j.vaccine.2012.07.055]

60. Parkin DM. The
global health burden of infection-associated cancers in the
year 2002. Int J Cancer 2006;118:3030-3044.

61. Lebelo RL,
Boulet G, Nkosi CM, et al. Diversity of HPV types in cancerous
and pre-cancerous penile lesions of South African men:
Implications for future HPV vaccination strategies. J Med
Virol 2013 (in press). [http://dx.doi.org/10.1002/jmv.23730]

62. Spiess PE,
Horenblas S, Pagliaro LC, et al. Current concepts in penile
cancer. J Natl Compr Canc Netw 2013;11(5):617-624.

63. Anic GM,
Giuliano AR. Genital HPV infection and related lesions in men.
Prev Med 2011;53(Suppl 1):S36-S41.

64. Habbous S, Chu
KP, Qiu X, et al. The changing incidence of human
papillomavirus-associated oropharyngeal cancer using multiple
imputation from 2000 to 2010 at a Comprehensive Cancer Centre.
Cancer Epidemiol 2013 (in press).
[http://dx.doi.org/10.1016/j.canep.2013.09.011]

65. Kreimer AR,
Clifford GM, Boyle P, Franceschi S, et al. Human
papillomavirus types in head and neck squamous cell carcinomas
worldwide: A systematic review. Cancer Epidemiol Biomarkers
Prev 2005;14:467-475.

66. Beachler DC,
D'Souza G. Oral human papillomavirus infection and head and
neck cancers in HIV-infected individuals. Curr Opin Oncol
2013;25(5):503-510.
[http://dx.doi.org/10.1097/CCO.0b013e32836242b4]

67. D'Souza G,
Kreimer AR, Viscidi R, et al. Case-control study of human
papillomavirus and oropharyngeal cancer. N Engl J Med
2007;356:1944-1956.

68. Beachler DC,
Weber KM, Margolick JB, et al. Risk factors for oral HPV
infection among a high prevalence population of HIV-positive
and at-risk HIV-negative adults. Cancer Epidemiol Biomarkers
Prev 2012;21(1):122-133.
[http://dx.doi.org/10.1158/1055-9965.EPI-11-0734]

69. Kreimer AR,
Alberg AJ, Daniel R, et al. Oral human papillomavirus
infection in adults is associated with sexual behavior and HIV
serostatus. J Infect Dis 2004;189:686-698.

70. Videla S,
Darwich L, Cañadas MP, et al. Natural history of human
papillomavirus infections involving anal, penile, and oral
sites among HIV-positive men. Sex Transm Dis 2013;40(1):3-10.
[http://dx.doi.org/10.1097/OLQ.0b013e31827e87bd]

71. D'Souza G,
Fakhry C, Sugar EA, et al. Six-month natural history of oral
versus cervical human papillomavirus infection. Int J Cancer
2007;121(1):143-150.

72. Ndiaye C,
Alemany L, Diop Y, et al. The role of human papillomavirus in
head and neck cancer in Senegal. Infect Agent Cancer
2013;8(1):14. [http://dx.doi.org/10.1186/1750-9378-8-14]

73. Pierce
Campbell CM, Lin HY, Fulp W, et al. Consistent condom use
reduces the genital human papillomavirus burden among
high-risk men: The HPV infection in men study. J Infect Dis
2013;208(3):373-384.
[http://dx.doi.org/10.1093/infdis/jit191]

74. Bleeker MC,
Hogewoning CJ, Voorhorst FJ, et al. HPV-associated flat penile
lesions in men of a non-STD hospital population: Less frequent
and smaller in size than in male sexual partners of women with
CIN. Int J Cancer 2005;113:36-41.

75. Tobian AA,
Gray RH. Male foreskin and oncogenic human papillomavirus
infection in men and their female partners. Future Microbiol
2011;6(7):739-745. [http://dx.doi.org/10.2217/fmb.11.59]

76. Giuliano AR,
Goldstone S, Moreira ED, et al. Efficacy of quadrivalent HPV
vaccine against HPV infection and disease in males. N Engl H
Med 2011;364:401-411.

77. Moscicki AB,
Palefsky JM. HPV in men: An update. J Low Genit Tract Dis
2012;15:231-234.
[http://dx.doi.org/10.1097/LGT.0b013e318203ae61]

78. Wilkin T, Lee
JY, Lensing SY, et al. Safety and immunogenicity of the
quadrivalent human papillomavirus vaccine in HIV-1-infected
men. J Infect Dis 2010;202(8):1246-1253.
[http://dx.doi.org/10.1086/656320]

79. Brisson M, van
de Velde N, Boily MC. Economic evaluation of
human papillomavirus vaccination in developed countries.
Public Health Genomics 2009;12:343-351.
[http://dx.doi.org/10.1159/000214924]

80. Ali H, Donovan
B, Wand H, et al. Genital warts in young Australians five
years into national human papillomavirus vaccination
programme: National surveillance data. BMJ 2013;346:f2032.
[http://dx.doi.org/10.1136/bmj.f2032]

81. Sandø N,
Kofoed K, Zachariae C, Fouchard J, et al. A reduced national
incidence of anogenital warts in young Danish men and women
after introduction of a national quadrivalent human
papillomavirus vaccination programme for young women – an
ecological study. Acta Derm Venereol 2013 (in press).
[http://dx.doi.org/10.2340/00015555-1721]

82. Stanley M.
Immune responses to human papillomavirus. Vaccine
2006;24(Suppl 1):S16-S22.